Wheeler Bio secures $35 million in oversubscribed Series A-1 round to accelerate growth, expand drug development and boost biomanufacturing capabilities
Wheeler Bio announced its successful completion of an oversubscribed Series A-1 financing round, meaning the Oklahoma City-based company attracted more investor interest and funding offers than initially sought, a strong indicator of confidence in the company’s growth and potential. The $35 million round was led by Alloy Therapeutics and Echo Investment Capital (Echo), with additional participation from Mitsubishi Corp. (Americas), Germin8 Ventures and Russell Westbrook Enterprises.